Sunshine Biopharma Q3 Loss Widens to $1.2M; $14.6M Cash Funds 29 Months
SBFM is trading near its 52-week low of $2.53 (11% above the low) on light trading volume (0.2× avg).
Summary
Sunshine Biopharma posted a wider Q3 loss of $1.2 million on flat $9.4 million revenue, yet ended September with $14.6 million in cash that management says funds about 29 months of operations.
Key Events · Earnings and Guidance · SBFM
-
Q3 Loss Widens on Higher Costs
Net loss was $1,223,940 for the three months ended September 30, 2026 versus $883,820 a year earlier, as revenue held flat at $9,442,325 and consulting and legal expenses rose.
-
Cash Position Funds 29 Months
Cash and cash equivalents reached $14,618,614 at September 30, 2026, up from $9,123,308 at December 31, 2025; management estimates this plus sales covers about 29 months at a ~$1.5 million quarterly cash deficit.
-
Nine-Month Revenue Slips 3.4%
Revenue for the nine months was $26,794,777 versus $27,728,750 a year earlier, and gross profit fell to $7,709,374 from $9,226,832 as cost of sales rose to 71.2% of revenue.
-
Share Count and Warrant Overhang Grow
Shares outstanding rose to 278,317 at September 30, 2026 from 24,530 at December 31, 2025, and the Series B Warrants were adjusted to 11,233,359 warrants at $2.7674 after the October 26, 2026 1-for-20 reverse split.
Analysis · SBFM · Life Sciences
Consulting and legal costs jumped, pushing the quarterly loss to $1,223,940 from $883,820 a year earlier even as revenue held flat at $9,442,325. The balance sheet matters more here: cash stood at $14,618,614 after the company raised $7.3M net from offerings and $2.7M from warrant exercises in the first nine months. Management says that cash plus sales covers roughly 29 months of operations at a ~$1.5 million quarterly burn, pushing any near-term financing need well into 2029. Against that, the share count keeps climbing — 278,317 shares at September 30 versus 24,530 at December 31, 2025, before the October 1-for-20 reverse split — and the Series B warrants were reset to 11,233,359 warrants at $2.7674 after the split, a large overhang over a company with a market value near $2 million.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SBFM was trading at $2.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2M. The 52-week trading range was $2.53 to $464.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.